aspirin + aluminum glycinate + magnesium carbonate (Iovance Biotherapeutics)

Bufferin A81 is a buffered aspirin combination tablet originally developed by Lion Co., Ltd. It contains 81 mg of aspirin as the active antiplatelet agent, combined with a buffering agent known as dialuminate (a mixture of aluminum glycinate and heavy magnesium carbonate) to mitigate gastrointestinal side effects. Aspirin acts by irreversibly inhibiting cyclooxygenase-1 (COX-1), thereby reducing the production of thromboxane A2 and inhibiting platelet aggregation. The product is indicated for the prevention and treatment of cardiovascular and cerebrovascular conditions, including angina pectoris, myocardial infarction, and ischemic stroke, as well as Kawasaki disease. Zhejiang Huahai Pharmaceutical is currently developing a generic version in China.

Brand names

Bufferin A81Bufferin combination tablets A81Bufferin 81-mg tabletsBufferin81-mg tabletsBufferin-81-mg tablets

Other names

aspirin/aluminum glycinate/magnesium carbonate tablets (II)dihydroxy aluminum aminoacetate, heavy magnesium carbonate and aspirin tablets (II)